You just read:

Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome

News provided by

Neurocrine Biosciences, Inc.

Dec 12, 2018, 07:30 ET